Strong Q1 revenue blows SciClone's slow boat to China
This article was originally published in Scrip
Executive Summary
SciClone Pharmaceuticals' transition to a China-focused specialty drug company appears to be on track as it reported an 81% year-over-year increase in first quarter revenue after fully integrating NovaMed into the fold toward the end of 2011.